Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McGill University

$27,000.00

Semaglutide as a Strategy to Alleviate Carbohydrate Counting Burden in Type 1 Diabetes

EF 2025-26

Résumé
Type 1 diabetes is a lifelong condition where the pancreas is damaged and can no longer make insulin. Insulin is a hormone that allows the body to use sugar from the food we eat for energy. People with this condition must take insulin several times a day and closely monitor their blood sugar levels. New technologies, like continuous glucose sensors and automated insulin pumps, work together to help manage diabetes. Glucose sensors track sugar levels throughout the day, and automated pumps adjust insulin based on these sugar levels. However, these systems still struggle to predict how much insulin is needed during meals. They require people to count the carbohydrates in the food they eat so the pump can calculate insulin doses. This daily task can be stressful, time-consuming, and difficult to do accurately. Our team is studying whether a medication called semaglutide (Ozempic®) can make Type 1 diabetes easier to manage. Semaglutide helps control blood sugar and appetite and is already approved for Type 2 diabetes. We want to see whether people with Type 1 diabetes, taking semaglutide, can reduce or simplify carbohydrate counting without worsening blood sugar control. We will run a clinical trial with 26 adults who use automated insulin pumps. The study will last 50 weeks, during which participants will take semaglutide for one half of the study and a placebo (salt water) for the other half. Throughout the study, participants will eliminate or simplify carbohydrate counting while we monitor their blood sugar and insulin needs. If successful, this study could make Type 1 diabetes easier to manage, improve quality of life, and help expand safe treatment options for people living with this condition.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573323
Name
Wright Carolyn
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Semaglutide as a Strategy to Alleviate Carbohydrate Counting Burden in Type 1 Diabetes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Adjunct Pharmacotherapy; Automated Insulin Delivery Systems; Carbohydrate Counting; Continuous Glucose Monitoring; Diabetes Technology; Glycemic Control; Insulin Therapy; Randomized Clinical Trial; Semaglutide; Type 1 Diabetes
Abstract
Type 1 diabetes is a lifelong condition where the pancreas is damaged and can no longer make insulin. Insulin is a hormone that allows the body to use sugar from the food we eat for energy. People with this condition must take insulin several times a day and closely monitor their blood sugar levels. New technologies, like continuous glucose sensors and automated insulin pumps, work together to help manage diabetes. Glucose sensors track sugar levels throughout the day, and automated pumps adjust insulin based on these sugar levels. However, these systems still struggle to predict how much insulin is needed during meals. They require people to count the carbohydrates in the food they eat so the pump can calculate insulin doses. This daily task can be stressful, time-consuming, and difficult to do accurately. Our team is studying whether a medication called semaglutide (Ozempic®) can make Type 1 diabetes easier to manage. Semaglutide helps control blood sugar and appetite and is already approved for Type 2 diabetes. We want to see whether people with Type 1 diabetes, taking semaglutide, can reduce or simplify carbohydrate counting without worsening blood sugar control. We will run a clinical trial with 26 adults who use automated insulin pumps. The study will last 50 weeks, during which participants will take semaglutide for one half of the study and a placebo (salt water) for the other half. Throughout the study, participants will eliminate or simplify carbohydrate counting while we monitor their blood sugar and insulin needs. If successful, this study could make Type 1 diabetes easier to manage, improve quality of life, and help expand safe treatment options for people living with this condition.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wright, Carolyn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~